Company intelligence / Profile preview

VERO Biotech

Atlanta, Georgia, United Statesvero-biotech.com ↗

Ownership: Private
Employees: ~247
Development stage: Other

Overview

VERO Biotech has developed and commercialized GENOSYL® Delivery System, the first FDA-approved tankless inhaled nitric oxide delivery system. The third-generation device is approved for use in hospitals and neonatal intensive care units, providing on-demand generation of inhaled nitric oxide without heavy gas tanks. Clinical adoption has been driven by its safety, portability, ease-of-use, and ability to address unmet needs in neonatal intensive care for PPHN. The company is expanding commercialization following recent funding.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Device (inhaled nitric oxide delivery system)Gas therapy (nitric oxide)
Industry: Therapeutic Medical Devices

Partnerships

Petrichor Capital Partners

Beyond the preview

Go deeper on VERO Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VERO Biotech.